- Home
- LDP vs PHAR Comparison
LDP vs PHAR Comparison
Compare LDP & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDP
- PHAR
- Stock Information
- Founded
- LDP 2012
- PHAR 1988
- Country
- LDP United States
- PHAR Netherlands
- Employees
- LDP N/A
- PHAR N/A
- Industry
- LDP Finance Companies
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- LDP Finance
- PHAR Health Care
- Exchange
- LDP Nasdaq
- PHAR Nasdaq
- Market Cap
- LDP 599.3M
- PHAR 679.0M
- IPO Year
- LDP N/A
- PHAR N/A
- Fundamental
- Price
- LDP $20.60
- PHAR $9.10
- Analyst Decision
- LDP
- PHAR Strong Buy
- Analyst Count
- LDP 0
- PHAR 3
- Target Price
- LDP N/A
- PHAR $27.00
- AVG Volume (30 Days)
- LDP 102.5K
- PHAR 6.7K
- Earning Date
- LDP 01-01-0001
- PHAR 03-13-2025
- Dividend Yield
- LDP 7.91%
- PHAR N/A
- EPS Growth
- LDP N/A
- PHAR N/A
- EPS
- LDP N/A
- PHAR N/A
- Revenue
- LDP N/A
- PHAR $285,745,000.00
- Revenue This Year
- LDP N/A
- PHAR $20.08
- Revenue Next Year
- LDP N/A
- PHAR $9.22
- P/E Ratio
- LDP N/A
- PHAR N/A
- Revenue Growth
- LDP N/A
- PHAR 30.64
- 52 Week Low
- LDP $16.16
- PHAR $6.65
- 52 Week High
- LDP $20.30
- PHAR $13.20
- Technical
- Relative Strength Index (RSI)
- LDP 53.49
- PHAR 46.44
- Support Level
- LDP $20.11
- PHAR $9.37
- Resistance Level
- LDP $20.63
- PHAR $10.01
- Average True Range (ATR)
- LDP 0.23
- PHAR 0.55
- MACD
- LDP 0.06
- PHAR -0.14
- Stochastic Oscillator
- LDP 90.07
- PHAR 16.26
About LDP Cohen & Steers Limited Duration Preferred and Income Fund Inc.
Cohen & Steers Ltd Duration Preferred & Income Fund, Inc. is a diversified, closed-end management investment company. Its primary investment objective is high current income and capital appreciation is its secondary investment objective. The Fund invests at least its managed assets in preferred and other income securities issued by U.S. and non-U.S. companies under normal market conditions.
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.